With USD 11.4 billion in 2022 and USD 29.3 billion by 2031 the global Drug Discovery Services Market is expected to increase at a CAGR of 14.1%. North America's better healthcare system and high R&D expenditure enable it to currently monopolize the market.
Strong market growth for drug discovery services is driven by rising need for new therapies, increasing prevalence of chronic diseases, and technical breakthroughs including artificial intelligence and machine learning in drug discovery processes. Pharmaceutical and biotechnology businesses are outsourcing drug discovery efforts to specialist contract research organizations (CROs) more and more in order to save expenses, obtain specialized knowledge, and accelerate the drug development schedule. This trend is projected to keep propelling market growth during the complete projection period.
Market Trend: Integration of artificial intelligence and machine learning in processes of drug development
Artificial intelligence (AI) and machine learning (ML) combined into drug development processes is revolutionizing the pharmaceutical industry. These instruments are helping to uncover prospective drug candidates, forecast their properties, and maximize lead molecule by means of large volumes of biological and chemical data analysis. AI-powered systems could save a lot of time and money connected with traditional drug development methods by permitting fast virtual screening of millions of compounds and predicting their efficacy and safety profiles. Apart from internal AI capabilities investments, this trend is driving collaboration between pharmaceutical companies and AI-oriented startups. Adoption of artificial intelligence and machine learning in drug research is expected to fasten and provide more economical and effective drug development procedures, thereby permitting faster launch of new medicines.
Market Driver: Rising incidence of chronic diseases and demand for novel therapies
The growing global frequency of chronic diseases like cancer, cardiovascular diseases, and neurological disorders drives most of the drug discovery services industry. As the world population ages and lifestyle-related health issues grow more common, creative and effective treatments are in higher demand. Rising research and development budgets in response to this by pharmaceutical and biotechnology companies have generated demand for particular drug discovery tools. Moreover, the emergence of targeted medicines and precision medicine fuels the ambition for improved drug discovery approaches to identify and offer customized treatments. The demand to satisfy unmet medical needs and the potential high returns on investment in successful drug concepts still drive the growth of the market for drug discovery services across many therapeutic areas.
Market Restraint: High costs and hazards related to drug research and development
The essentially costly, time-consuming, and hazardous drug research and development process substantially limits the market for drug discovery services. Given the large portion of this investment done in the early discovery and preclinical stages, the average cost of bringing a new drug to market can exceed billions of dollars. Moreover, the failure rate in drug development is really important; many fascinating molecules fail in clinical trials due of lack of efficacy or safety concerns. This high-risk environment may dissuade certain pharmaceutical companies—especially for rare diseases or diseases with limited patient populations—from heavily investing in medication discovery. Strict legal constraints and the complexity of biological systems pose still more challenges to drug research. Particularly for smaller biotech firms with limited resources, these factors may limit market growth and lead to conservative drug discovery technology expenditure.
Biology Services Rules the Market
The area of biology services most in demand in the drug discovery services sector right now is This preponderance can be better understood in light of the growing relevance on focused treatments and the complexity of biological targets. Among the many broad range activities essential to the drug discovery process falling under biology services are target identification and validation, assay development, high-throughput screening, in vitro and in vivo research. The segment's rise is being driven by developments in genomics, proteomics, and other omics technologies—which have improved our understanding of disease processes and potential therapeutic targets. Moreover raising the demand for specialized biology services in medication development are biologics and cell and gene therapies.
Leading worldwide market North America's regional analysis of drug discovery services
North America dominates the globe of drug discovery services with the largest market share. Large R&D expenditure, a robust pharmaceutical and biotechnology sector in the area, and a legal framework that supports explain its leadership. Many of the largest pharmaceutical companies worldwide call North America—especially the United States—home, and a thriving biotech industry calls here home as well. Modern research facilities, large public and private funding for drug research, and a highly qualified staff benefit the area. Moreover, the presence of eminent academic institutions and research centers motivates innovation and teamwork in drug discovery. North America's strong intellectual property protection and streamlined laws inspire even more investment in drug exploration and development. Moreover, the area's early adoption of innovative technologies such artificial intelligence and high-throughput screening in drug development processes has verified its industry leadership. Since pharmaceutical companies continuing outsourcing drug discovery efforts to specialized CROs, North America's market leadership is probably steady over the foreseeable period.
The drug discovery services market is defined by fierce competition and a mix of well-known multinational corporations and specialized niche players. Major pharmaceutical companies, full-service contract research organizations (CROs), and specialist boutique firms are among the competitors vying for market share. To enhance their service offerings, industry players employ important strategies including strategic partnerships, mergers and acquisitions, and advanced technology investments. Companies increasingly value the development of integrated drug discovery platforms integrating artificial intelligence-driven methodologies with in silico technologies and traditional wet lab techniques. The market also shows collaboration between pharma companies and educational institutions to gain creative research and technologies. As the need for outsourced drug development services keeps growing, companies are spreading their global footprint, particularly in underdeveloped areas, to capture fresh chances and give fairly priced solutions to their clients.
Charles River Laboratories
Evotec SE
Laboratory Corporation of America Holdings
Thermo Fisher Scientific Inc.
Eurofins Scientific
WuXi AppTec
Pharmaron
GenScript Biotech Corporation
Jubilant Biosys Ltd.
Syngene International Limited
Albany Molecular Research Inc. (AMRI)
Domainex Ltd.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022- 2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global Drug Discovery Services Market (2018 – 2022)
3.2. Global Drug Discovery Services Market (2023 – 2031)
3.2.1. Market Segment By Service Type (2023 – 2031)
3.2.2. Market Segment By Process (2023 – 2031)
3.2.3. Market Segment By Drug Type (2023 – 2031)
3.2.4. Market Segment By Therapeutic Area (2023 – 2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Integration of AI and machine learning in drug discovery processes
4.1.2. Increasing adoption of organ-on-a-chip technology
4.1.3. Rise of collaborative drug discovery ecosystems
4.2. Market Drivers
4.2.1. Rising prevalence of chronic diseases and demand for novel therapeutics
4.2.2. Growing outsourcing of drug discovery services
4.2.3. Advancements in genomics and proteomics technologies
4.3. Market Restraints
4.3.1. High costs and risks associated with drug discovery and development
4.3.2. Stringent regulatory requirements
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY SERVICE TYPE (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Medicinal Chemistry
5.2. Biology Services
5.3. Drug Metabolism and Pharmacokinetics (DMPK)
6. BY PROCESS
6.1. Target Selection
6.2. Target Validation
6.3. Hit-To-Lead Identification
6.4. Lead Optimization
7. BY DRUG TYPE
7.1. Small Molecules
7.2. Biologics
8. BY THERAPEUTIC AREA
8.1. Oncology
8.2. Neurology
8.3. Infectious Diseases
8.4. Cardiovascular Diseases
8.5. Others
9. GEOGRAPHY
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. South America
9.2.1. Brazil
9.2.2. Argentina
9.2.3. Rest of South America
9.3. Europe
9.3.1. Germany
9.3.2. United Kingdom
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle-East
9.5.1. UAE
9.5.2. Saudi Arabia
9.5.3. Turkey
9.5.4. Rest of Middle East
9.6. Africa
9.6.1. South Africa
9.6.2. Egypt
9.6.3. Rest of Africa
10. COMPETITVE LANDCAPE
10.1. Key Developments
10.2. Company Market Share Analysis
10.3. Product Benchmarking
11. SWOT ANALYSIS
12. COMPANY PROFILES
12.1. Charles River Laboratories
12.2. Evotec SE
12.3. Laboratory Corporation of America Holdings
12.4. Thermo Fisher Scientific Inc.
12.5. Eurofins Scientific
12.6. WuXi AppTec
12.7. Pharmaron
12.8. GenScript Biotech Corporation
12.9. Jubilant Biosys Ltd.
12.10. Syngene International Limited
12.11. Albany Molecular Research Inc. (AMRI)
12.12. Domainex Ltd. (*LIST NOT EXHAUSTIVE)
13. MARKET OPPORTUNITIES
By Service Type:
Medicinal Chemistry
Biology Services
Drug Metabolism and Pharmacokinetics (DMPK)
By Process:
Target Selection
Target Validation
Hit-To-Lead Identification
Lead Optimization
By Drug Type:
Small Molecules
Biologics
By Therapeutic Area:
Oncology
Neurology
Infectious Diseases
Cardiovascular Diseases
Others
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
